| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
a Division of General Thoracic Surgery, Mayo Clinic, Rochester, Minnesota
b Division of Biostatistics, Mayo Clinic, Rochester, Minnesota
c Division of Radiation Oncology, Mayo Clinic, Rochester, Minnesota
d Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota
Accepted for publication November 3, 2008.
* Address correspondence to Dr Nichols, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905 (Email: nichols.francis{at}mayo.edu).
Presented at the Fifty-fourth Annual Meeting of the Southern Thoracic Surgical Association, Bonita Springs, FL, Nov 7–10, 2007.
Background: Neoadjuvant chemoradiotherapy followed by esophagogastrectomy has become the standard of care for patients with locally advanced esophageal cancer. This report analyzes our experience with this treatment approach.
Methods: From January 1998 through December 2003, all patients from a single institution receiving neoadjuvant chemoradiotherapy followed by esophagogastrectomy were reviewed for operative mortality, morbidity, long-term survival, and factors affecting survival. Only patients preoperatively staged with both computed tomographic scans and endoscopic ultrasound were included.
Results: There were 162 patients (142 men, 20 women), and the median age was 61 years (range, 22 to 81 years). Histopathology was adenocarcinoma in 143 patients and squamous cell in 19. Pretreatment clinical stage was II in 28 patients (17%), III in 111 (68%), and IV (M1a) in 23 (14%). Ivor Lewis esophagogastrectomy was the most common procedure, occurring in 132 patients. Operative mortality and morbidity was 4.9% and 37%, respectively. Pathologic response was complete in 42 patients (26%), near complete in 27 (17%), partial in 88 (54%), and unresectable in 5 (3%). Five-year survival for overall, complete, near complete, and partial response patients was 34%, 55%, 27%, and 27%, respectively (p = 0.013). Patients whose lymph nodes were rendered free of cancer showed improved overall and disease-free survival compared with patients having persistently positive lymph nodes (p = 0.019).
Conclusions: Esophagogastrectomy after neoadjuvant chemoradiotherapy can be performed with low mortality and morbidity. Patients with complete pathologic response have significantly improved long-term survival compared with patients with near complete and partial responses. Future efforts should be directed at understanding determinants of complete responses.
This article has been cited by other articles:
|
|
 |
|
  P.-K. Hsu, L.-I. Chien, C.-S. Huang, C.-C. Hsieh, Y.-C. Wu, W.-H. Hsu, and T.-Y. Chou Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all? Interact CardioVasc Thorac Surg, May 31, 2013; (2013) ivt216v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Ajani, A. M. Correa, W. L. Hofstetter, D. C. Rice, M. A. Blum, A. Suzuki, T. Taketa, J. Welsh, S. H. Lin, J. H. Lee, et al. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer Ann. Onc., October 1, 2012; 23(10): 2638 - 2642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Rizk, E. L. Servais, L. H. Tang, C. S. Sima, H. Gerdes, M. Fleisher, V. W. Rusch, and P. S. Adusumilli Tissue and Serum Mesothelin Are Potential Markers of Neoplastic Progression in Barrett's Associated Esophageal Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., March 1, 2012; 21(3): 482 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Stiles, F. Mirza, A. Coppolino, J. L. Port, P. C. Lee, S. Paul, and N. K. Altorki Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease Ann. Thorac. Surg., August 1, 2011; 92(2): 491 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Ajani, M. A. Blum, J. Welsh, W. L. Hofstetter, and S. G. Swisher Celebrate or Calibrate? We Say Calibrate J. Clin. Oncol., July 1, 2011; 29(19): 2732 - 2732. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Monjazeb, G. Riedlinger, M. Aklilu, K. R. Geisinger, G. Mishra, S. Isom, P. Clark, E. A. Levine, and A. W. Blackstock Outcomes of Patients With Esophageal Cancer Staged With [18F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET): Can Postchemoradiotherapy FDG-PET Predict the Utility of Resection? J. Clin. Oncol., November 1, 2010; 28(31): 4714 - 4721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Shen, K. M. Harrison-Phipps, S. D. Cassivi, D. Wigle, F. C. Nichols III, M. S. Allen, C. M. Wood, and C. Deschamps Esophagectomy after anti-reflux surgery J. Thorac. Cardiovasc. Surg., April 1, 2010; 139(4): 969 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Tomaszek, S. D. Cassivi, M. S. Allen, K. R. Shen, F. C. Nichols III, C. Deschamps, and D. A. Wigle An alternative postoperative pathway reduces length of hospitalisation following oesophagectomy, Eur J Cardiothorac Surg, April 1, 2010; 37(4): 807 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Stiles, P. Christos, J. L. Port, P. C. Lee, S. Paul, J. Saunders, and N. K. Altorki Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer J. Thorac. Cardiovasc. Surg., February 1, 2010; 139(2): 387 - 394. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
